Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events

Proteasome inhibitors, e.g. Bortezomib (BTZ) and Carfilzomib (CFZ), have demonstrated clinical efficacy against haematological cancers. Interestingly, several adverse effects are less common, compared to BTZ, in patients treated with CFZ. As the molecular details of these observations remain not wel...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsakiri, Eleni N., Terpos, Evangelos, Papanagnou, Eleni-Dimitra, Kastritis, Efstathios, Brieudes, Vincent, Halabalaki, Maria, Bagratuni, Tina, Florea, Bogdan I., Overkleeft, Herman S., Scorrano, Luca, Skaltsounis, Alexios-Leandros, Dimopoulos, Meletios A., Trougakos, Ioannis P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736585/
https://www.ncbi.nlm.nih.gov/pubmed/29259189
http://dx.doi.org/10.1038/s41598-017-17596-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736585/
https://www.ncbi.nlm.nih.gov/pubmed/29259189
http://dx.doi.org/10.1038/s41598-017-17596-4

Ejemplares similares